- Trial phase
- Approved
- Time to market
- Already approved and marketed since 1995.
- Why 3/10
- Genotropin is an already-approved, marketed drug with no pending regulatory decision or pivotal readout scheduled in the next 12 months. It is a small, declining product within Pfizer's massive $63B+ portfolio and not among the top 10 revenue drivers. The defining binary catalysts (initial FDA approval, label expansions) are long past. Impact score is 3 per the rubric: an approved drug with no upcoming binary catalyst.
There are no near-term binary catalysts for Genotropin. Watch for updates on the reusable pen device shortage (expected to last until at least early 2027) and for continued erosion of market share to biosimilar Omnitrope and Pfizer's own once-weekly NGENLA. For Pfizer investors, the drug is a minor, declining contributor within a $63B+ portfolio.
Price Chart
Executive Summary
Genotropin (somatropin) is Pfizer's recombinant human growth hormone, FDA-approved since the 1990s for multiple pediatric and adult growth disorders. It is a mature, off-patent product facing biosimilar competition (Sandoz's Omnitrope) and internal cannibalization from Pfizer's own once-weekly long-acting growth hormone NGENLA (somatrogon). Genotropin is not among Pfizer's top 10 revenue drivers and represents a very small portion of Pfizer's $63 billion annual revenue. The drug has no upcoming binary catalysts, and its reusable pen device has been in shortage since early 2026. For a Pfizer investor, Genotropin is a legacy product in slow decline, not a needle-moving asset.
How It Works
Genotropin is a synthetic (recombinant) version of human growth hormone, the natural hormone produced by the pituitary gland that stimulates growth in children and helps maintain normal body composition in adults. It is injected under the skin and works by binding to growth hormone receptors throughout the body, stimulating the production of insulin-like growth factor 1 (IGF-1), which promotes bone and muscle growth.
Trial Status
Genotropin has been FDA-approved since 1995 and is a commercially marketed product. The original NDA (020280) has been supplemented multiple times to add indications including pediatric growth hormone deficiency, Prader-Willi syndrome, Small for Gestational Age, Turner syndrome, Idiopathic Short Stature, and adult growth hormone deficiency. No new pivotal trials are ongoing for this molecule; Pfizer's growth hormone focus has shifted to its once-weekly product NGENLA (somatrogon).
The Two-Sided Case
Upcoming Catalysts
- No upcoming regulatory catalysts for Genotropin specifically. The reusable pen device shortage is expected to last until at least early 2027. Pfizer's growth hormone strategy has shifted to NGENLA (once-weekly somatrogon).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report